CuraVac Launches Its Investment Campaign on Spreds

The countdown has begun: two months to raise (and exceed!) €500,000. Two months to secure the funding needed to finance the final steps of CV-MG01 before market entry. Two months to achieve this objective, bringing us one step closer to a durable treatment for myasthenia gravis—first in dogs, and ultimately in other animals and humans.

By launching its crowdfunding campaign on Spreds, CuraVac aims to finalize the development of its veterinary treatment for myasthenia gravis. In July 2026, the European Medicines Agency (EMA) stated in a Scientific Advice that the efficacy data with dogs is sufficient to proceed to a Marketing Authorization Application. The final step lies in the manufacturing and validation of a commercial veterinary batch of CV-MG01.

With veterinary market entry expected in 2028, the product rollout will provide further proof of concept for the company's Targeted Active Therapy (TAT) platform. Such a milestone would strengthen the platform's notoriety within the scientific community and increase the value of the company while helping attract future investors interested in supporting Phase 2 and Phase 3 clinical development in humans.

With a market of approximately 3,000 dogs treated annually by neurologist vets across Europe and the United States, the therapy addresses a market currently estimated at €11.5 million. It is estimated that the actual market could be three times bigger, as many dogs die before receiving specialist care. Revenues generated through product sales and licensing agreements from 2028 onward will then be reinvested directly into funding the clinical development of CV-MG02, intended for human use (expected in 2032).

It is worth noting that every euro invested in CuraVac's research and development activities will be matched through a repayable advance granted by the Walloon Region, that will finance up to 55% of the R&D budget.

Since its creation in 2003, CuraVac has secured more than €18 million in funding, enabling the development of CV-MG01, the successful completion of its Phase 1b clinical trial, and the creation of a more potent formulation for human applications. More recently, two compassionate administrations of CV-MG01 to dogs suffering from severe forms of myasthenia gravis both resulted in remission within only a few weeks. These encouraging outcomes add to the growing body of evidence supporting CV-MG01 as CuraVac moves towards veterinary commercialisation and the continued development of its TAT platform for human applications. 

See where we stand in our crowdfunding campaign on Spreds.